Vision Incubate Invests in CAR-T Drug Discovery Firm Optium Biotechnologies
Key facts
- Vision Incubate Invests in CAR-T Drug Discovery Firm Optium Biotechnologies
- Vision Incubate has invested in Optium Biotechnologies, a firm specializing in CAR array generation technology, to accelerate the development of their cancer therapy, 'OPTF01'.
- Source: PR Times
- Date: June 12, 2026
Direct answer
Vision Incubate has invested in Optium Biotechnologies, a firm specializing in CAR array generation technology, to accelerate the development of their cancer therapy, 'OPTF01'.
- Citation
- Vision Incubate Invests in CAR-T Drug Discovery Firm Optium Biotechnologies (June 12, 2026), PR Times
- Source
- PR Times
- Date
- June 12, 2026
Vision Incubate has invested in Optium Biotechnologies, a firm specializing in CAR array generation technology, to accelerate the development of their cancer therapy, 'OPTF01'.
📋 Article Processing Timeline
- 📰 Published: June 12, 2026 at 14:00
- 🔍 Collected: June 12, 2026 at 05:21
- 🤖 AI Analyzed: June 12, 2026 at 06:25 (1h 3m after Collected)
Vision Incubate Co., Ltd. invested in Optium Biotechnologies, Inc. in April 2026. Optium is a biotech company driving drug discovery research using the 'Eumbody System,' a CAR array generation technology originating from Ehime University. They are currently preparing for clinical trials of 'OPTF01,' an anti-FAPa CAR-T cell that targets tumor cells and the tumor microenvironment.
The investment aligns with Vision Incubate's mission to bridge academia-based research results to societal implementation, given their high assessment of Optium's innovative technology. This funding will accelerate preparations for starting US clinical trials for glioblastoma. Optium aims to provide new treatment options for intractable solid tumors.
The investment aligns with Vision Incubate's mission to bridge academia-based research results to societal implementation, given their high assessment of Optium's innovative technology. This funding will accelerate preparations for starting US clinical trials for glioblastoma. Optium aims to provide new treatment options for intractable solid tumors.
FAQ
どの企業が出資を行いましたか？
株式会社ビジョンインキュベイトです。
出資先のオプティアム社はどのような企業ですか？
CAR配列創製技術「Eumbody System」を用いた次世代のCAR-T細胞療法を研究開発するバイオテクノロジー企業です。
資金はどのように活用されますか？
主力の臨床パイプライン「OPTF01」の膠芽腫を対象とした米国臨床試験開始に向けた準備に使われます。
OPTF01とはどのような薬剤ですか？
腫瘍細胞及び腫瘍微小環境を標的とする抗FAPa CAR-T細胞です。
ビジョンインキュベイトのミッションは何ですか？
アカデミア発の優れた研究成果を社会実装につなげることです。